OXFORD, MS - This is a news release from Cloaked Therapeutics, LLC
Cloaked Therapeutics, LLC and Monvida Pharmaceuticals, LLC announced today that they have entered into a collaboration to develop TumorSelect® Paclitaxel for all oncology indications. Under the agreement, Monvida gains Chinese and Vietnamese development and commercial rights. Cloaked retains rights in all other world markets.
TumorSelect® Paclitaxel is a novel reformulation of paclitaxel that promises to improve both its efficacy and tolerability when compared with standard Cremophor® as well as newer formulations. Since paclitaxel's issues can be traced to its well-characterized PK/PD limitations, investigators expect that improvements in paclitaxel's PK/PD profile should directly relate to improved clinical outcomes. TumorSelect® Paclitaxel has overcome those limitations as demonstrated by its superior efficacy in established breast cancer preclinical mouse models:
TumorSelect® Paclitaxel is better tolerated than standard Cremophor® paclitaxel
Non-target tissue concentrations of paclitaxel are significantly lower in non-tumored and tumored mice injected with TumorSelect® Paclitaxel compared with mice injected with Cremophor® paclitaxel
Tumor concentrations of paclitaxel are significantly higher in mice injected with TumorSelect® Paclitaxel
Plasma and heart concentrations of paclitaxel are significantly lower in tumored vs. non-tumored animals
TumorSelect® overcomes the limitations of previous nanoparticle technologies by using a proprietary particle design that utilizes naturally occurring components and Microfluidizer® high shear fluid processor technology. TumorSelect® offers a straight forward low cost approach with early proof-of-concept for the creation of proprietary NCEs utilizing known effective compounds. In addition, the technology can enable novel compounds that might otherwise be difficult to formulate.
"Cloaked is very pleased to enter into a collaboration with Monvida that promises to improve cancer care for millions of patients," James D. McChesney, PhD, Chairman and CEO of Cloaked.
"Traditional chemotherapeutics will continue to be a mainstay of cancer treatment for years to come," said Sam Nguyen, PhD, CEO of Monvida. "Cloaked's technology promises to improve cancer treatment outcomes while reducing toxicities. Cloaked achieves better PK/PD improvements with reformulated paclitaxel that are as good as or better than any other current nanoparticle technology."